21
Results for year ended 31 December 2016 Ewan Phillips, CEO Jonathan Shaw, FD April 2017

Ewan Phillips, CEO Jonathan Shaw, FD ... - Deltex Medical · Results for year ended 31 December 2016 Ewan Phillips, CEO Jonathan Shaw, FD April 2017

Embed Size (px)

Citation preview

Results for year ended 31 December 2016

Ewan Phillips, CEOJonathan Shaw, FD

April 2017

Proven: ODM fluid management halves

post-op complications

2© 2016

© 2017

• Consumable revenues up 5% at £5.8m (2015: £5.5m)

• US probe revenues up 40% to £1.9m• 28 platform a/cs at 31 December, up from 17

• 25% growth in local currency with sterling sales overtaking UK

• International probe revenues up 25% at £1.7m

• UK probe revenues down 26% at £1.9m• Signs of stabilisation: new probes and new evidence

• Gross margin on consumables up to 74% (2015: 70%)

• Monitor revenues down £0.2m at £0.4m

• Cash position £0.6m: additional £0.4m raised in March

Financial highlights – 2016 progress

3

© 2017

• Probe revenues returned to growth: up 14% on H2 15• Strong growth in export markets: volumes up plus pound weaker

• H2: US up 40%, International up 30%

• H2 UK down 17% (H1: down 36%)

• Substantially reduced operating loss• H2 operating loss £0.6m down >50% (H2 15: £1.3m)

• £1m+ annualised cost savings before forex came through in H2

• Substantially reduced cash consumption• H2 operating loss before non-cash costs of £0.2m (H2 15: £1.0m)

• H2 total cash consumption halved to <£0.4m

Financial highlights – second half progress

4

© 2017

• 30th US platform account in place from January• Redeploying US resources to better match platform distribution

• March probe margin higher than fixed staff costs for first time

• UK Q1 2017 revenues slightly ahead of Q1 2016• 10% fall in probe revenues offset by monitor sales and 3rd party

• International on track but behind Q1 2016• Increased monthly probe order from France; other regulars up or maintained

• Timing differences on low margin monitor orders

• All probe tip assembly in-house from January: £30,000+ per month saving

• Successful field trials of embedded impedance technology: launch pending

• EU pilot grant €50,000 awarded re VP loop Graphical User Interface

YTD 2017 progress

5

© 2017

US platform accounts

© 2017

Newsflow forward look

US expansion programme• Traction in platform accounts

• Adding new accounts

– Platform type

– System cross-selling

New product development• Multi-modal workstation concept

– Non-invasive HD ICG

– Velocity Pressure loops – TruVue GUI

• Digital QI – marketing programmes

• Broadening market – animals

7

© 2017

Summary

• US growth rate continuing to improve

• Target of 30 platform accounts• Achieved in January: 28 at year end

• Focus shift from evaluations to implementations: spread best practice

• Redeploying resources to match platform constituents

• March first month where probe margin covered regular US staff costs

• UK trends improving, signs of stabilising

• Manufacturing margin improvement validated and underway

• Positioned for returns from investment in product development

8

© 2017

Appendices

9

© 2017

Appendix A

Summary financial information

10

© 2017

Appendix A –2016 results – Pro-forma

11

2016£’000

2015£’000

Probes 5,458 5,230

Other consumables 331 259

Total consumables 5,789 5,489

Gross profit 4,306 3,855

Sundry income / (expense) (5) (6)

Net monitor income / (costs) 28 (15)

Cash costs (6,176) (6,716)

Cash loss before USA investment costs (1,847) (2,882)

Non cash costs (522) (253)

US market development costs - (351)

Operating loss (2,369) (3,486)

© 2017

Appendix A - Balance sheet assets and liabilities

12

Liabilities Dec 16£’000

Dec15£’000

Trade & other payables 2,414 2,766

Borrowings - current 858 1,864

Borrowings - >1 year 967 34

Provisions 119 117

4,358 4,781

Assets Dec 16£’000

Dec 15£’000

Non-current assets

Intangible assets 2,396 2,006

Property, plant and equipment 431 573

2,827 2,579

Current assets

Inventories 760 805

Trade & other receivables 2,499 2,621

Tax recoverable 107 125

Cash at bank and in hand 582 575

3,948 4,126

© 2017

Appendix B

13

Addressing previously unmet clinical need

Proven: ODM fluid management halves

post-op complications